Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab

Journal of Clinical Oncology

Volumn 28, Issue 28, 2010, Pages

  Kelly, Ronan J ^a   Carter, Corey ^b   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PF 299804; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; QUINAZOLINONE DERIVATIVE; VINBLASTINE;

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; DISEASE COURSE; LUNG TUMOR; MIDDLE AGED; PERSONALIZED MEDICINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINONES; VINBLASTINE;

EID: 78049451972     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.3126     Document Type: Article

References (25)

1. Langer CJ, Stephenson P, Thor A, et al: Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22:1180-1187, 2004 (Pubitemid 41079829)
2. Johnson BE, Janne PA: Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small-cell lung cancer. Clin Cancer Res 12:4436s-4440s, 2006
3. Zinner RG, Glisson BS, Fossella FV, et al: Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small-cell lung cancer: Report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44:99-110, 2004 (Pubitemid 38317266)
4. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small-cell lung carcinomas. Br J Cancer 86:1449-1456, 2002 (Pubitemid 34548069)
5. Heinmoller P, Gross C, Beyser K, et al: HER2 status in non-small-cell lung cancer: Results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 9:5238-5243, 2003
6. Hirsch FR, Franklin WA, Veve R, et al: HER2/neu expression in malignant lung tumors. Semin Oncol 29:51-58, 2002 (Pubitemid 34226519)
7. Clamon G, Herndon J, Kern J, et al: Lack of trastuzumab activity in non-small-cell lung carcinoma with overexpression of erb-B2: 39810: A phase II trial of Cancer and Leukemia Group B. Cancer 103:1670-1675, 2005 (Pubitemid 40490028)
8. Krug LM, Miller VA, Patel J, et al: Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced non-small-cell lung carcinoma. Cancer 104:2149-2155, 2005 (Pubitemid 41579961)
9. Gatzemeier U, Groth G, Butts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19-27, 2004 (Pubitemid 38139598)
10. Herbst RS, Davies AM, Natale RB, et al: Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non-small-cell lung cancer. Clin Cancer Res 13:6175-6181, 2007 (Pubitemid 350075078)
11. Smylie M, Blumenschein GR Jr, Dowlati A, et al: A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small-cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. J Clin Oncol 25:7611, 2007 (suppl)
12. Ramlau R, Thomas M, Plummer R, et al: Phase I study of lapatinib, a dual-tyrosine kinase inhibitor, and pemetrexed in the second-line treatment of advanced or metastatic non-small-cell lung cancer. J Clin Oncol 27:e19027, 2009
13. Johnson DH, Arteaga CL: Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial? J Clin Oncol 21:2227-2229, 2003 (Pubitemid 46621854)
14. Graus-Porta D, Beerli RR, Daly JM, et al: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997 (Pubitemid 27151960)
15. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small-cell lung cancer Is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
16. Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small-cell lung cancer. Clin Cancer Res 10:136-143, 2004 (Pubitemid 38114172)
17. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23:5007-5018, 2005 (Pubitemid 46224007)
18. Nakamura H, Kawasaki N, Taguchi M, et al: Association of HER-2 overexpression with prognosis in non-small-cell lung carcinoma: A metaanalysis. Cancer 103:1865-1873, 2005
19. Engelman JA, Zejnullahu K, Gale CM, et al: PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932, 2007
20. Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646, 2005 (Pubitemid 40478587)
21. Janne PA, Schellens JH, Engelman JA, et al: Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 26:8027, 2008
22. Janne PA, Reckamp K, Koczywas M, et al: Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial. J Clin Oncol 27:8063, 2009
23. Papila C, Uzun H, Balci H, et al: Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors. Med Oncol 26:151-156, 2009
24. Ardizzoni A, Cafferata MA, Paganuzzi M, et al: Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced non-small-cell lung carcinoma. Cancer 92:1896-1904, 2001
25. Cappuzzo F, Bemis L, Varella-Garcia M: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354:2619-2621, 2006 (Pubitemid 43882374)